Key Market Indicators
Sales of Italian medicines for blood and blood forming organs are set to reach $2.7 billion by 2026. This is a 0.5% increase on the 2021 figure of $2.6 billion. Since 2016, the Italian market has grown at an average annual rate of 2.9%. In 2021, Italy ranked third, behind Germany at $2.6 billion and South Korea at $2.5 billion. The prevalence of anemia in Italy is projected to decline 1% a year to 37,570 hospital discharges by 2026. This is a drop from 40,120 discharges in 2021. Since 2006, Italian demand has fallen by 1.9% a year. In 2021, Poland overtook Italy, with 40,120 discharges. Germany, the United Kingdom and Poland were numbers 2, 3 and 4, respectively, in the ranking.
